Loading clinical trials...
Loading clinical trials...
ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX
Conditions
Interventions
fitusiran
Bypassing agents
Locations
58
United States
Investigational Site Number 0117
Phoenix, Arizona, United States
Investigational Site Number 0139
Los Angeles, California, United States
Investigational Site Number 0135
Orange, California, United States
Investigational Site Number 0137
San Diego, California, United States
Investigational Site Number 0128
Gainesville, Florida, United States
Investigational Site Number 0115
Jacksonville, Florida, United States
Start Date
February 14, 2018
Primary Completion Date
November 25, 2020
Completion Date
June 23, 2021
Last Updated
March 28, 2022
NCT06379789
NCT07226206
NCT05987449
NCT06008938
NCT04645199
NCT07080905
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions